Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that data in multiple preclinical models showed that GKT831, the Company’s NOX ...
Archamps (France) and Geneva (Switzerland), June 28th, 2017 at 6:00pm CEST. Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today ...
Archamps (France) and Geneva (switzerland), June 27th, 2017 at 6:00 pm CEST Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX.pa), a biopharmaceutical company and the leader in NOX therapies, announced to ...
Geneva, Switzerland, 19 June 2017 - 7:30am CEST : - GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that the first patient ha ...
Geneva (Switzerland), 12 june 2017 - 7:30am CEST : - GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced tod ...
Toulouse and Geneva, May 2nd, 2017 Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that the U.S. Food & Drug Administra ...
